Amsterdam, June 2, 2014 -- Elsevier, world-leading provider of scientific, technical and medical information products and services, and the Research Network of Computational and Structural Biotechnology (RNCSB), announce their collaborative relationship in publishing open access journal, Computational and Structural Biotechnology Journal (CSBJ).
Computational and Structural Biotechnology Journal will be published on behalf of the Research Network of Computational and Structural Biotechnology. RNCSB is a non-profit society dedicated to the advancement of the science of biotechnology, chem-bioinformatics, systems biology and nanoscience through publication of scientific journals, organizing scientific workshops/conferences and promoting the diversity of individuals entering the advanced biotechnology scientific workforce.
Computational and Structural Biotechnology Journal is an international online-only, open access journal which publishes high quality research articles and reviews. The focus is on a functional and mechanistic understanding of how molecular components in a biological process work together through the application of computational methods. All content is indexed in PubMed Central immediately upon publication.
The Editor-in-Chief of the journal, Gianni Panagiotou, Associate Professor, at The University of Hong Kong, said of the launch, "We are pleased to work with Elsevier to publish Computational and Structural Biotechnology Journal to provide a high quality open access publishing option for authors in this important field. We are excited by this new opportunity for our authors and readers who will benefit from the breadth of Elsevier's reach and the innovative multi-media functionalities offered on ScienceDirect. We view Elsevier as being on the cutting edge in terms of their understanding of communication and the global dissemination of knowledge. At the end of the day, what makes a journal successful is: (1) the people involved, and (2) how those people connect to the broader community."
"We are delighted to announce our publishing agreement with RNCSB. For the past two years, RNCSB has applied a creative and democratic approach to open access publishing and has built a strong reputation for quality publications in this field through conference and author outreach initiatives. CSBJ will be a strong addition to Elsevier's the open access publications," said Kaia Motter, Publisher at Elsevier.
Computational and Structural Biotechnology Journal will publish its first issue with Elsevier in June 2014.
For more information or to submit an article, go to: http://ees.
About Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish open access in over 1,600 established peer-reviewed journals as well as over 100 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+ 31 20 485 2759